An intravenous formulation of cultured adult human mesenchymal stem cells proposed to treat acute and steroid-refractory graft-versus-host disease in patients who have undergone allogeneic hematopoietic stem cell transplantation.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Betrixaban for Atrial Fibrillation
An oral factor Xa inhibitor for the prevention of stroke in patients with nonvalvular atrial fibrillation.
Stomaphyx™
A transoral endoluminal fastening device for gastric pouch/stoma reduction after failed bariatric bypass surgery.
Zephyr® Endobronchial Valve
Endoscopically implanted one-way valves used as an alternative to lung volume reduction surgery for palliative treatment of heterogeneous emphysema.
Incivek™ (Telaprevir)
An oral protease inhibitor for the treatment of hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
Pradaxa® (Dabigatran Etexilate) for Prevention of Venous Thromboembolism (VTE) Following Hip or Knee Replacement
An oral anticoagulant for prevention of venous thromboembolism (VTE) following major orthopedic surgery.
Prolia® (Denosumab) for Bone Loss Due to Hormone Ablation Therapy
A twice-yearly, injected, antiresorptive biologic agent that is being developed for the prevention and treatment of bone loss due to hormone ablation therapies for breast or prostate cancer.
Synergy® Neurostimulator
An implantable pulse generator being developed as an occipital nerve stimulator for the management of medically refractory chronic migraine headache.
Crizotinib (Xalkori®)
An oral kinase inhibitor for the treatment of non-small-cell lung cancer for patients with an abnormal ALK gene.
Brentuximab Vedotin (Adcetris™) for Hodgkin Lymphoma
An intravenous agent for the treatment of patients with refractory or relapsed Hodgkin lymphoma.